Brainsway Ltd. Sponsored ADR (BWAY) shares rallied 9.4% in the last trading session to close at $5.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock’s 1.9% loss over the past four weeks.
New coverage policies in the past month are likely driving the prospect of Brainsway as these policies provide access to a larger patient population.
This company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of -33.3%. Revenues are expected to be $8.35 million, up 19.1% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Brainsway Ltd. Sponsored ADR, the consensus EPS estimate for the quarter has been revised 7.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BWAY going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Brainsway Ltd. Sponsored ADR is part of the Zacks Medical – Products industry. Perrigo (PRGO), another stock in the same industry, closed the last trading session 0.4% lower at $41.82. PRGO has returned 12.5% in the past month.
For Perrigo
, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.43. This represents a change of -14% from what the company reported a year ago. Perrigo currently has a Zacks Rank of #3 (Hold).
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report